Unravel the Secrets to 5772% Profit: Exclusive Interview with Bybit’s WSOT Champion Maksim
DUBAI, UNITED ARAB EMIRATES - Media OutReach - 23 October 2023 - Ever wondered how…
2 years ago
GPE Launches Virtual Reality Film on Climate Change And Education
WASHINGTON D.C., MAPUTO - Media OutReach - 23 October 2023 - The Global Partnership for…
2 years ago
Genexine and KGbio received the first market approval for novel long-acting Erythropoietin, Efepoetin alfa, from The Indonesian Food and Drug Authority (BPOM)
First market approval for Genexine discovered and developed therapeutic drug, Efesa (Efepoetin alfa), a long-acting…
2 years ago
National Football League Teams Up with SES for Game Content Distribution
In a renewed partnership, SES’s hybrid distribution network to enable the NFL to reach over…
2 years ago
Celltrion, Inc. & Celltrion Healthcare Co., Ltd. Announce Shareholders Approval of Merger
On October 23rd, at the EGM of shareholders, the merger agreement between Celltrion, Inc. &…
2 years ago
Nidec Announces Financial Results for Fiscal Second Quarter and Six Months Ended September 30, 2023
KYOTO, Japan--(BUSINESS WIRE)--Nidec Corporation (TOKYO:6594) (OTC US:NJDCY) today announced its consolidated financial results under the…
2 years ago
Nidec Announces Differences between Projected and Actual Financial Results for First-Half FY2023
KYOTO, Japan--(BUSINESS WIRE)--Nidec Corporation (TOKYO: 6594; OTC US: NJDCY) (the “Companyâ€) today announced differences between…
2 years ago
Ramagrama Stupa the Sole Undisturbed Original Stupa Containing Relics of Lord Buddha to be Preserved and Developed
LUMBINI, NEPAL - Media OutReach - 23 October 2023 - The Promised Land is pleased…
2 years ago
FHA-HoReCa announces new initiatives and partnerships for 2024 edition, covering Technology Solutions and Talent recognition
Anticipate the debut of first-ever FSTEC Asia – catering to the surging demand for technology…
2 years ago
ENHERTU® Approved in the EU as the First HER2 Directed Therapy for Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer
Approval based on DESTINY-Lung02 trial results where Daiichi Sankyo and AstraZeneca’s ENHERTU demonstrated a confirmed…
2 years ago